What monoclonal antibody(s) should be used for a patient with moderate‑to‑severe eosinophilic esophagitis who has failed dietary elimination and swallowed topical steroids?

Monoclonal Antibodies for Eosinophilic Esophagitis

Dupilumab is the only FDA-approved monoclonal antibody for moderate-to-severe eosinophilic esophagitis in patients who have failed dietary elimination and swallowed topical steroids, and it should be your first-line biologic choice. 1, 2

FDA-Approved Biologic Therapy

• Dupilumab (Dupixent®) is approved in the United States, Europe, and Canada for patients ≥12 years of age (≥40 kg in Europe) who are unresponsive to, intolerant of, or not candidates for conventional therapies (PPIs, topical steroids, dietary elimination). 1, 3

• Dupilumab blocks both IL-4 and IL-13 pathways by targeting the IL-4 receptor alpha chain, addressing the core type 2 inflammatory mechanism driving EoE. 1, 4

• In pediatric patients aged 1–11 years, dupilumab achieved histologic remission (≤6 eosinophils/HPF) in 68% at higher exposure and 58% at lower exposure versus 3% with placebo at 16 weeks, with sustained improvements through 52 weeks. 5

• Dupilumab significantly improves not only histologic inflammation but also endoscopic scores (EREFS), dysphagia symptoms, and esophageal distensibility—addressing both inflammatory and fibrostenotic disease components. 6, 2

Biologics That Have Failed or Are Not Recommended

• Anti-IL-5 therapies (mepolizumab, reslizumab, benralizumab) are explicitly not recommended for EoE treatment due to lack of efficacy or unfavorable safety profiles. 7, 1

• The 2020 AGA/Joint Task Force guidelines state that anti-IL-5 therapy should be used only in the context of a clinical trial, reflecting insufficient evidence for routine clinical use. 7

• Omalizumab (anti-IgE) is conditionally recommended against for EoE treatment due to very low-quality evidence of benefit. 7, 1

• Vedolizumab (anti-α4β7), infliximab (anti-TNF), and lirentelimab (anti-Siglec-8) have all failed to demonstrate efficacy and should not be used. 1

Clinical Decision Algorithm for Biologic Use

Step 1: Confirm treatment failure of conventional therapies

• Document inadequate response to at least 8–12 weeks of twice-daily PPI therapy (e.g., omeprazole 20–40 mg BID). 8
• Document inadequate response to swallowed topical corticosteroids (fluticasone or budesonide) for 8–12 weeks. 8
• Document failure of or inability to adhere to empiric elimination diet (two-food, four-food, or six-food elimination). 8

Step 2: Verify histologic non-response

• Perform repeat endoscopy with biopsies from multiple esophageal sites while the patient remains on treatment; symptom improvement alone does not indicate histologic healing. 8, 2
• Histologic remission is defined as <15 eosinophils/HPF; failure to achieve this threshold despite conventional therapy qualifies the patient for dupilumab. 8, 2

Step 3: Initiate dupilumab

• Administer dupilumab subcutaneously according to FDA-approved weight-based dosing for pediatric patients or standard adult dosing. 1, 5
• Continue dupilumab as long-term maintenance therapy; relapse rates are extremely high after drug withdrawal. 8, 2

Step 4: Monitor response

• Reassess with endoscopy and biopsy at 16 weeks to document histologic, endoscopic, and clinical response. 5, 2
• Continue monitoring clinical symptoms, endoscopic findings, and histology over time to assess for sustained remission and guide long-term management. 2

Safety Profile and Common Adverse Events

• In pediatric trials, the most common adverse events with dupilumab (≥10 percentage points higher than placebo) were COVID-19, nausea, injection-site pain, and headache. 5

• Serious adverse events occurred in 3 patients during the initial 16-week treatment period and 6 patients overall through 52 weeks, but dupilumab did not increase overall adverse event rates compared to placebo. 5, 6

• Dupilumab has a well-established safety profile from its use in multiple atopic diseases (atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis), providing reassurance for long-term use in EoE. 1, 4

Critical Pitfalls to Avoid

• Do not assume symptom resolution equals histologic healing—approximately 41% of patients report symptomatic improvement without true histologic remission, risking ongoing inflammation and fibrosis. 8

• Do not use anti-IL-5 monoclonal antibodies (mepolizumab, reslizumab, benralizumab) outside of clinical trials—these have failed to demonstrate efficacy and are explicitly not recommended by current guidelines. 7, 1

• Do not delay dupilumab in patients with severe dysphagia, food impaction, or stricture formation—these represent advanced fibrostenotic disease requiring aggressive anti-inflammatory therapy combined with endoscopic dilation when indicated. 2

• Do not discontinue dupilumab after achieving remission without a clear plan for alternative maintenance therapy—relapse rates are extremely high after biologic withdrawal, similar to topical steroid cessation. 8, 2

Positioning Dupilumab in the Treatment Algorithm

• Dupilumab is reserved for patients who have documented failure of conventional therapies (PPIs, topical steroids, dietary elimination) based on both clinical and histologic assessments. 1, 3, 2

• The 2025 ACG guidelines recommend dupilumab as a treatment option for EoE, positioning it alongside PPIs, topical steroids, empiric diet elimination, and esophageal dilation in the therapeutic arsenal. 2

• Dupilumab is particularly valuable for patients with multiple type 2 inflammatory conditions (atopic dermatitis, asthma, allergic rhinitis) who may benefit from treating all comorbidities with a single agent. 1, 4, 9

• For patients with esophageal strictures causing dysphagia, combine dupilumab with conservative endoscopic dilation (balloon or bougie) to address both inflammation and mechanical obstruction. 8, 2